WASHINGTON, Aug. 19, 2008 (LAWFUEL) — The law firm of
Finkelstein Thompson LLP is currently investigating potential
shareholder claims for breach of fiduciary duty arising from the
proposed merger of APP Pharmaceuticals, Inc. (“APPX”) with Fresenius,
SE (“Fresenius”).
On July 7, 2008, APPX announced its plan to merge with Fresenius for
cash and a future amount to be determined according to a Contingent
Value Rights Agreement, both of which had been pre-approved. Fresenius
and APPX’s Chairman, Patrick Soon-Shiong (“Soon-Shiong”) together hold
over 80% of APPX’s outstanding shares. The merger agreement also
contains a $140 million termination fee and a “no solicitation”
agreement. As such, it appears that this merger may be unfair to APPX
shareholders.
If you currently hold APPX securities, please contact FT’s Washington,
DC office at (877) 337-1050 or by email at
contact@finkelsteinthompson.com to discuss your rights.
